Genome-wide association analyses identify variants in *IRF4* associated with acute myeloid leukemia and myelodysplastic syndrome susceptibility

Junke Wang[1¥], Alyssa I. Clay-Gilmour[2¥], Ezgi Karaesmen[1], Abbas Rizvi[1], Qianqian Zhu[3], Li Yan[3], Leah Preus[1], Song Liu[3], Yiwen Wang[1], Elizabeth Griffiths[4], Daniel O. Stram[5], Loreall Pooler[5], Xin Sheng[5], Christopher Haiman[5], David Van Den Berg[5], Amy Webb[6], Guy Brock[6], Stephen Spellman[7], Marcelo Pasquini[8], Philip McCarthy[9], James Allan[10], Friedrich Stölzel[11], Kenan Onel[12], Theresa Hahn[4¥], Lara E. Sucheston-Campbell[1,13¥]

[1]College of Pharmacy, The Ohio State University
[2]Department of Epidemiology, Mayo Clinic
[3]Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center
[4]Department of Medicine, Roswell Park Comprehensive Cancer Center
[5]Department of Preventive Medicine, University of Southern California
[6]Department on Biomedical Informatics, The Ohio State University
[7]Center for International Blood and Marrow Transplant Research, Minneapolis Campus
[8]Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin
[9]Department of Medicine, Roswell Park Comprehensive Cancer Center
[10]Northern Institute for Cancer Research, Newcastle University, UK
[11]Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden,
[12]Department of Pediatrics, Mount Sinai
[13]College of Veterinary Medicine, The Ohio State University
¥ Joint first and joint last authors

Running head: GWAS in AML and MDS
Keywords: acute myeloid leukemia, myelodysplastic syndrome, genome-wide association study, blood and marrow transplantation, pleiotropy
Word Count: 3754

Conflicts of interest: None

Corresponding author:
Lara E. Sucheston-Campbell, MS, PhD, The Ohio State University, 496 W. 12th Ave., 604 Riffe Building, Columbus, OH 43210; email: sucheston-campbell.1@osu.edu; phone: 614-688-2502

ABSTRACT

The role of common genetic variation in susceptibility to acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), a group of rare clonal hematologic disorders characterized by dysplastic hematopoiesis and high mortality, remains unclear. We performed AML and MDS genome-wide association studies (GWAS) in the DISCOVeRY-BMT cohorts (2309 cases and 2814 controls). Association analysis based on subsets (ASSET) was used to conduct a summary statistics SNP-based analysis of MDS and AML subtypes. For each AML and MDS case and control we used PrediXcan to estimate the component of gene expression determined by their genetic profile and correlate this imputed gene expression level with risk of developing disease in a transcriptome-wide association study (TWAS). ASSET identified an increased risk for *de novo* AML and MDS (OR=1.38, 95% CI, 1.26-1.51, $P_{meta}=2.8x10^{-12}$) in patients carrying the T allele at rs12203592 in *Interferon Regulatory Factor 4* (*IRF4*), a transcription factor which regulates myeloid and lymphoid hematopoietic differentiation. Our TWAS analyses showed increased *IRF4* gene expression is associated with increased risk of *de novo* AML and MDS (OR=3.90, 95% CI, 2.36-6.44, $P_{meta}=1.0x10^{-7}$). The identification of *IRF4* by both GWAS and TWAS contributes valuable insight on the role of genetic variation in AML and MDS susceptibility.

INTRODUCTION

Genome-wide association studies (GWAS) have been successful at identifying risk loci in several hematologic malignancies, including acute myeloid leukemia (AML) [1-3]. Recently genomic studies have identified common susceptibility loci between chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), and multiple myeloma demonstrating shared genetic etiology between these B-cell malignancies (BCM) [4-6]. Given the evidence of a shared genetic basis across BCM and the underlying genetic predisposition for AML and myelodysplastic syndromes (MDS) observed in family, epidemiological, and genetic association studies[1,7-9], we hypothesized that germline variants may contribute to both AML and MDS development. Using the DISCOVeRY-BMT study population (2309 cases and 2814 controls), we performed AML and MDS GWAS in European Americans and used these data sets to inform our hypothesis. To address the disease heterogeneity within and across our data we used a validated meta-analytic association test based on subsets (ASSET) [4]. ASSET tests the association of SNPs with all possible AML and MDS subtypes and identifies the strongest genetic association signal. To systematically test the association of genetically predicted gene expression with disease risk, we performed a transcriptome wide association study (TWAS)[10,11]. This allows a preliminary investigation into the role of non-coding risk loci, which might be regulatory in nature, that impact expression of nearby genes. The TWAS statistical approach, PrediXcan [11], was used to impute tissue-specific gene expression from a publicly available whole blood transcriptome panel into our AML and MDS cases and controls. The predicted gene expression levels were then tested for association with AML and MDS. The use of both a GWAS and TWAS in the DISCOVeRY-BMT study

population allowed us to identify AML and MDS associations with *IRF4*, a transcription factor which regulates myeloid and lymphoid hematopoietic differentiation, and has been previously identified in GWAS of BCM.(5)

MATERIALS AND METHODS

Study Design & Population

Our study was a nested case-control design derived from the parent study DISCOVeRY-BMT (Determining the Influence of Susceptbility COnveying Variants Related to 1-Year Mortality after unrelated donor Blood and Marrow Transplant).[12] The DISCOVeRY-BMT cohort was compiled from 151 centers around the world through the Center for International Blood and Marrow Transplant Research (CIBMTR). Briefly, the parent study was designed to find common and rare germline genetic variation associated with survival after an URD-BMT. DISCOVeRY-BMT consists of two cohorts of ALL, AML and MDS patients and their 10/10 human leukocyte antigen (HLA)-matched unrelated healthy donors. Cohort 1 was collected between 2000 and 2008, Cohort 2 was collected from 2009-2011.

AML and MDS patients were selected from the DISCOVeRY-BMT patient cohorts and used as cases and all the unrelated donors from both cohorts as controls. AML subtypes included *de novo* AML with normal cytogenetics, *de novo* AML with abnormal cytogenetics and therapy-related AML (t-AML). *De novo* AML patients did not have precedent MDS, chemotherapy or radiation for prior cancers. MDS subtypes included *de*

67 *novo* MDS, defined as patients without precedent chemotherapy or radiation for prior
68 cancers, and therapy-related MDS (t-MDS). Patient cytogenetic subtypes were available,
69 however due to limited sample sizes for each cytogenetic risk group, we consider here
70 only broad categories. Controls were unrelated, healthy donors aged 18-61 years who
71 passed a comprehensive medical exam and were disease-free at the time of donation.
72 All patients and donors provided written informed consent for their clinical data to be used
73 for research purposes and were not compensated for their participation.
74
75 **Genotyping, imputation, and quality control**
76 Genotyping and quality control in the DISCOVeRY-BMT cohort has previously been
77 described in detail [12-15]. Briefly, samples were assigned to plates to ensure an even
78 distribution of patient characteristics and genotyping was performed at the University of
79 Southern California Genomics Facility using the Illumina Omni-Express BeadChip®
80 containing approximately 733,000 single nucleotide polymorphisms (SNPs).[16] SNPs were
81 removed if the missing rate was > 2.0%, minor allele frequency (MAF) < 1%, or for
82 violation of Hardy Weinberg equilibrium proportions ($P < 1.0 \times 10^{-4}$).
83
84 Problematic samples were removed based on the SNP missing rate, reported-genotyped
85 sex mismatch, abnormal heterozygosity, cryptic relatedness, and population outliers.
86 Population stratification was assessed via principal components analysis using Eigenstrat
87 software[17] and a genomic inflation factor (λ) was calculated for each cohort. Following
88 SNP quality control, 637,655 and 632, 823 SNPs from the OmniExpress BeadChip in
89 Cohorts 1 and 2, respectively were available for imputation. SNP imputation was

90 performed using Haplotype Reference Consortium, hg19/build 37 (http://www.haplotype-
91 reference-consortium.org/home) via the Michigan Imputation server [18,19]. Variants with
92 imputation quality scores <0.8 and minor allele frequency (MAF) <0.005 were removed
93 yielding almost 9 million high quality SNPs available for analysis in each cohort.
94
95 **METHODS**
96 **Statistical Analysis**
97 *Genome-wide SNP associations with AML and MDS*
98 Quality control and statistical analyses were implemented using QCTOOL-v2, R 3.5.2
99 (Eggshell Igloo), Plink-v1.9, and SNPTEST-v2.5.4-beta3. Logistic regression models
100 adjusted for age, sex, and three principal components were used to perform single SNP
101 tests of association with *de novo* MDS, t-MDS, AML by subtype (*de novo* AML with normal
102 cytogenetics, *de novo* AML with abnormal cytogenetics and t-AML) in each cohort.
103 European American healthy donors were used as controls. SNP meta-analyses of
104 cohorts 1 and 2 were performed by fitting random effects models.[20] To identify the
105 strongest association signal with AML and MDS we conducted a summary statistic SNP-
106 based association analysis (ASSET) implemented in R statistical software [4]. ASSET tests
107 each SNP for association with outcome using an exhaustive search across non-
108 overlapping AML and MDS case groups while accounting for the multiple tests required
109 by the subset search, as well as any shared controls between groups [4].
110
111 *Heritability estimation of AML and MDS*

112 We calculated heritability of AML and MDS combined and by independent subtypes as
113 the proportion of phenotypic variance explained by all common genotyped SNPs, using
114 the genome-based restricted maximum likelihood method performed with the Genome-
115 wide Complex Trait Analysis (GCTA) software.[21-23] We report heritability on the observed
116 scale due to genome-wide genotyped variants as well as heritability on the liability scale
117 assuming AML and MDS disease prevalence of 0.0001.[24-26]
118
119 *Transcriptome-wide association study (TWAS) of AML and MDS*
120 To prioritize GWAS findings and identify expression quantitative trait loci (eQTL)-linked
121 genes, we carried out a gene expression tests of association of *de novo* AML and MDS
122 using PrediXcan[11]. This method leverages the well-described functional regulatory
123 enrichment in genetic variants relatively close to the gene body (i.e. *cis*-regulatory
124 variation) to inform models relating SNPs to gene expression levels in data with both gene
125 expression and SNP genotypes available. Robust prediction models are then used to
126 estimate the effect of cis-regulatory variation on gene expression levels. Using imputation,
127 the cis-regulatory effects on gene expression from these models can be predicted in any
128 study with genotype measurements, even if measured gene expression is not available.
129 Thus, we imputed the cis-regulatory component of gene expression into our data for each
130 individual using models trained on the whole blood transcriptome panel (n = 922) from the
131 Depression Genes and Networks (DGN)[27], yielding expression levels of 11,200 genes for
132 each case and control. The resulting estimated gene expression levels were then used
133 to perform gene-based tests of differential expression between AML and MDS cases and
134 controls adjusted for age and sex. A fixed effects model with inverse variance weighting

135 using the R package `Metafor` was used for meta-analysis of cohorts 1 and 2. A
136 Bonferroni-corrected transcriptome wide significance threshold was set at $P<4.5x10^{-6}$.
137
138 **Functional Annotation of Genetic Variation associated with AML and MDS**
139 To better understand the potential function of the variants identified by GWAS and ASSET
140 analyses we annotated significant SNPs using publicly available data. eQTLGen, a
141 consortium analyses of the relationship of SNPs to gene expression in 30,912 whole
142 blood samples, was used to determine if significant and suggestive SNPs ($p<5 \times 10^{-6}$)
143 were whole blood *cis*-eQTL, defined as allele specific association with gene expression
144 [28]. Genotype-Tissue Expression project (GTEx) was used to test for significant eQTLs in
145 >70 additional tissues [29]. AML and MDS SNP associations were also placed in context of
146 previous GWAS using Phenoscanner, a variant-phenotype comprehensive database of
147 large GWAS, which includes results from the NHGRI-EBI GWAS catalogue, the UK
148 Biobank, NIH Genome-Wide Repository of Associations between SNPs and Phenotypes
149 and publicly available summary statistics from more than 150 published genome
150 association studies. Results were filtered at $P < 5 \times 10^{-8}$ and the R statistical software
151 package `phenoscanner` (https://github.com/phenoscanner/phenoscanner) was used to
152 download all data for our significant variants[30]. Chromatin state data based on 25-state
153 Imputation Based Chromatin State Model across 24 Blood, T-cell, HSC and B-cell lines
154 was downloaded from the Roadmap Epigenomics project
155 (https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmMod
156 els/imputed12marks/jointModel/final/)[31]. Figures including chromatin state information
157 and results from previous GWAS were constructed using the R Bioconductor package

158 `gviz` [32-34]. Lastly, we sought to identify promoter interaction regions (PIR), defined as
159 significant interactions between gene promotors and distal genomic regions. Variants in
160 PIRs can be connected to potential gene targets and thus can impact gene function [34].
161 Briefly Hi-C libraries, enriched for promoter sequences, are generated with biotinylated
162 RNA baits complementary to the ends of promoter-containing restriction fragments.
163 Promoter fragments become bait for pieces of the genome that are targets with which
164 they frequently interact, allowing regulatory elements and enhancers to be pulled down
165 and sequenced. Statistical tests of bait-target pairs are done to define significant PIRs
166 and their targets [32,35,36]. To identify the genomic features with which our significant SNPs
167 might be interacting via chromatin looping we used publicly available Promoter Capture
168 Hi-C (PCHi-C) data on a lymphoblastoid cell line (LCL), GM12878, and two *ex vivo* $CD34^+$
169 hematopoietic progenitor cell lines (primary hematopoietic G-CSF mobilized stem cells
170 and hematopoietic stem cells) [35]. We integrated our SNP data with the PCHi-C cell line
171 data and visualized these interactions using circos plots [37].
172

173 **RESULTS**

174 *DISCOVeRY-BMT cases and controls*

175 Results of quality control have been described elsewhere.[14] Following quality control, the
176 DISCOVeRY-BMT cohorts include 1,769 AML and 540 MDS patients who received URD-
177 BMT as treatment and 2,814 unrelated donors as controls (**Table 1**). The majority of AML
178 cases are *de novo* (N=1618) with normal cytogenetics (N=543), 6% of patients had
179 therapy-related AML (t-AML). The most frequently reported previous cancers in patients
180 with t-AML were breast (N=51), non-Hodgkin Lymphoma (NHL), N=23, HL (N=14),

181 Sarcoma (N=12), Gynecologic (N=8), Acute Lymphoblastic Leukemia (N=6) and
182 Testicular (N=6). Prior therapies for these patients were approximately equally divided
183 between single agent chemotherapy and combined modality chemotherapy plus
184 radiation. Almost half of MDS patients had Refractory Anemia with Excess Blasts (RAEB)
185 -1 and RAEB-2. Of patients with t-MDS (~18% of MDS patients), 65% had antecedent
186 hematologic cancers or disorders. The most frequently reported antecedent cancers in
187 MDS patients were NHL (N=27), breast (N=15), Acute Lymphoblastic Leukemia (N=8),
188 HL (N=8), AML (N=8), Sarcoma (N=6) and CLL (N=5) (**Table 1**). Overall, the distribution
189 of antecedent cancers differed significantly between t-MDS and t-AML, with almost 2/3 of
190 t-MDS and 1/3 of t-AML patients diagnosed with a prior hematologic cancer.
191
192 *SNP Associations with AML and MDS*
193 GWAS of AML by subtype (abnormal cytogenetics, normal cytogenetics and t-AML) and
194 MDS (*de novo* and t-MDS) are shown in **Supplemental Figure 1**. No population
195 stratification was observed in PCA analysis and λ=1.0 in both cohorts.
196 To identify loci that show association with AML and MDS we used ASSET. For SNPs to
197 be considered, we used previously defined criteria, which required ASSET SNP
198 associations at $P \leq 5.0 \times 10^{-8}$ with significant individual one-sided subset tests ($P < 0.01$),
199 the variant association could not be driven by a single disease nor could it be both
200 positively and negatively associated in different cohorts of the same disease.[5] In the
201 ASSET GWAS analyses we identified a novel typed SNP associated with AML and MDS
202 on Chromosome 6 (**Figure 1**). The T allele at rs12203592, a variant in intron 4 of
203 *Interferon Regulatory Factor 4* (*IRF4*), conferred increased risk of *de novo* abnormal

204 cytogenetic AML, *de novo* normal cytogenetic AML, MDS and t-MDS (OR=1.38; 95% CI,
205 1.26-1.51, P_{meta}=2.8 x 10^{-12}). T-AML showed no association with rs12203592. The effect
206 allele frequency was 19% in *de novo* AML, MDS and t-MDS cases versus 14% in controls.
207 ASSET analyses also identified another variant in modest linkage disequilibrium (LD),
208 r^2=.7, with rs12203592 in the regulatory region of *IRF4*; the A allele at rs62389423,
209 showed a putative association with de novo AML and MDS (OR=1.36; 95% CI, 1.21-1.52,
210 P_{meta}=1.2x10^{-7}) (**Figure 2a**).
211 We identified one significant association in the subtype GWAS which was disease
212 specific. The C allele in rs78898975 in TATA-box binding protein associated factor 2
213 (*TAF2*), associated with an increased risk of t-MDS (OR_{meta}= 5.87 , 95% CI = 3.20, 10.76,
214 P_{meta}=9.9 x 10^{-9}) but not *de novo* MDS (OR= 1.8, 95% CI=.81, 1.45, P_{meta}=.20)
215 (**Supplemental Figure 1**). The effect allele frequency was 7% in t-MDS, 2% in *de novo*
216 MDS and 1.5% in controls.
217 A previous genome-wide association study of AML done in European American cases
218 and controls reported a susceptibility variant in *BICRA* (rs75797233) [38]. The variant was
219 not significantly associated with AML risk in our meta-analyses (OR=1.08, 95% CI=.78-
220 1.37). However, their cohort did not include patients who received an allogeneic
221 transplant as curative therapy and the distribution of AML subtypes differed between the
222 studies. In addition, the lower frequency (MAF=.02) of this imputed this variant (info score
223 >.8 in both cohorts) possibly reduced power to detect an effect.
224
225 **Functional Annotation of SNP associations with AML and MDS**

226 Multiple GWAS of healthy individuals have shown associations between the T allele at
227 rs12203592 and higher eosinophil counts, lighter skin color, lighter hair, less tanning
228 ability, and increased freckling.[30,39] GWAS have also identified associations between this
229 allele and increased risk of childhood acute lymphoblastic leukemia in males, non-
230 melanoma skin cancer, squamous cell carcinoma, cutaneous squamous cell carcinoma,
231 basal cell carcinoma, actinic keratosis, and progressive supranuclear palsy (**Figure 2b**).[30]
232 Furthermore, analyses of multiple B-cell malignancies recently identified a rs9392017,
233 adjacent to *IRF4*, as a pleiotropic susceptibility variant associated with both CLL and
234 Hodgkin Lymphoma(HL) [5,33,35,40]. This SNP is approximately 40Kb away from
235 rs12203592, although not in LD (r^2=.01).
236 The rs12203592 risk allele associated with increased expression of *IRF4*, P=1.48x10^{-29}
237 in whole blood[28]. *IRF4* is a key transcription factor for lymphoid and myeloid
238 hematopoiesis [41-44] and rs12203592 resides in a regulatory region across Blood, HSC, B-
239 Cell and T-Cell lines (**Figure 2c**). The variant's regulomedb score indicates how likely a
240 variant is to be a regulatory element from 1a (most likely) to 7 (no data); the variant's
241 score of 2b, indicates the variant is likely to affect transcription factor binding[45]. While the
242 HL and CLL pleiotropic variant rs9392017 was not a significant eQTL for *IRF4* in whole
243 blood, PCHi-C cell line data from both GM12878 and the *ex vivo* $CD34^+$ hematopoietic
244 progenitor cell lines show chromatin looping between rs9392017 and the regulatory
245 region containing rs12203592 (**Supplemental Figure 2**).
246 The t-MDS associated C allele in rs78898975 is correlated with significantly lower
247 expression of *TAF2* (P=1.95 x 10^{-13}) and *DEPTOR* (P= 4.7 x 10^{-9}) gene expression in
248 whole blood.[28,46]

249

250 **Heritability estimates of AML and MDS**

251 The heritability of AML and MDS on the observed scale due to genotyped variants was
252 0.46 with standard error (SE)=0.07. Transforming this to the liability scale and assuming
253 a disease prevalence of 0.0001 resulted in a heritability of 0.10 (SE=.02) which differed
254 significantly from a heritability of zero ($P=2.0 \times 10^{-16}$). The proportion of variance in *de*
255 *novo* AML with normal cytogenetics and *de novo* MDS on the liability scale had similar
256 heritability at 9%, SE=.03, $P=1.9 \times 10^{-3}$ and 14%, SE=.04, $P=1.4 \times 10^{-4}$, respectively.
257 Treatment-related AML and MDS were tested independently and estimated proportion of
258 variance explained by all SNPs was 7% for t-AML and 4% for t-MDS, however SE were
259 high and the heritability did not significantly differ from zero.

260

261 **Transcriptome-wide association study - PrediXcan**

262 Using PrediXcan[11] gene expression imputation models trained on the DGN data set, we
263 identified one transcriptome wide significant gene associated with *de novo* AML and
264 MDS. Increased expression of *IRF4* was associated with an increased risk for the
265 development of *de novo* AML and MDS (OR=3.90; 95% CI, 2.36-6.44, $P_{meta}=1.0 \times 10^{-7}$),
266 consistent with our SNP-level findings (**Figure 3**).

267 Whole blood transcriptome models also identified two additional genes with suggestive
268 associations with *de novo* AML and MDS. Increased expression of AKT Serine/Threonine
269 Kinase 1, *AKT1* at 14q32.33 was associated with risk for the development of *de novo*
270 AML and MDS (OR=1.56; 95% CI, 1.25-1.95, $P_{meta}=1.0 \times 10^{-4}$) (Figure 4). Likewise,
271 increased expression of Ras guanyl nucleotide-releasing protein 2, *RASGRP2*, was

272 associated with an increased risk for development of *de novo* AML and MDS (OR=4.05;
273 95% CI, 1.84-8.91, $P_{meta}=5x10^{-4}$) (**Figure 4**).
274
275 **DISCUSSION**
276 We performed the first large scale AML and MDS GWAS in a URD-BMT population
277 providing evidence of novel pleotropic risk loci associated with increased susceptibility to
278 AML and MDS. We identified an association between the T allele at rs12203592 in *IRF4*
279 and an increased risk for the development of *de novo* AML, *de novo* MDS and t-MDS in
280 patients who had undergone URD-BMT compared to healthy donor controls. While
281 therapy-related myeloid neoplasms have been shown to be genetically and etiologically
282 similar to other high-risk myeloid neoplasms[47], in our transplant population t-AML did not
283 associate with this variant, while t-MDS did show evidence of association with
284 rs12203592. We also identified a genome-wide significant t-MDS variant which was an
285 eQTL for both *TAF2* and *DEPTOR* genes. We also provide the first estimates of the
286 heritability of AML and MDS, at between 9-14%, which are in line with other GWAS of
287 cancer heritability on the liability scale, indicating that genetic variation contributes to AML
288 and MDS susceptibility.[48]
289 The rs12203592 SNP has been shown to regulate *IRF4* transcription by physical
290 interaction with the *IRF4* promoter through a chromatin loop[49]. This SNP resides in an
291 important position within *NFkB* motifs in multiple blood and immune cell lines, supporting
292 the hypothesis that this SNP may modulate *NFkB* repression of *IRF4* expression.[50,51]
293 Furthermore, this SNP resides in a hematopoietic transcription factor that has been
294 previously identified to harbor a hematological cancer susceptibility locus, rs9392017,

295 which we show interacts with the region containing our susceptibility variant. These data
296 add to the mounting evidence that there could be pleiotropic genes across multiple
297 hematologic cancers[5,52-55].
298 Imputed gene expression logistic regression models showed a significant association
299 between higher predicted levels of *IRF4* expression and the risk for development of *de*
300 *novo* AML or MDS[11]. Although *IRF4* functions as a tumor suppressor gene in early B-cell
301 development [56], in multiple myeloma *IRF4* is a well-established oncogene[44], with
302 oncogenic implications extending to adult leukemias[57] and lymphomas[58], as well as
303 pediatric leukemia. *IRF4* overexpression is a hallmark of activated B-cell-like type of
304 diffuse large B-cell lymphoma and associated with classical Hodgkin lymphoma (cHL),
305 plasma cell myeloma and primary effusion lymphoma.[59] In a case-control study of
306 childhood leukemia increased *IRF4* expression was higher in immature B-common acute
307 lymphoblastic leukemia and T-cell leukemia with the highest expression levels in pediatric
308 AML patients compared to controls[60]. In addition to the CLL genetic susceptibility loci
309 identified in *IRF4,* high expression levels of the gene have been shown to correlate with
310 poor clinical prognosis [61].
311 TWAS studies can be a powerful tool to help prioritize potentially causal genes. It is,
312 however, imperative to investigate the SNP and gene-expression associations in the
313 context of the surrounding variants and genes to reduce the possibility of a false signal
314 from co-regulation. Co-regulation can occur when there are multiple GWAS and TWAS
315 hits due to linkage disequilibrium and thus it becomes difficult to determine which locus
316 is driving the phenotypic association. In our study, the SNP rs12203592 is a significant
317 eQTL for only *IRF4*, this implies that the SNP and imputed gene expression signal we

318 identified is not being driven by co-regulation of neighboring SNPs and/or genes. When
319 considering non-imputed gene expression sets, eQTLgen[28] corroborates this finding;
320 rs12230592 is significantly associated with only increased expression of *IRF4*. In addition,
321 the relationship of rs12203592 to *IRF4* expression in blood seems tissue specific, as
322 GTEx data across over 70 tissues shows association with only lung tissue at $P=9.1x10^{-9}$.
323 The specificity of rs12203592 to *IRF4* expression in blood and the lack of correlation
324 between *IRF4* expression and other genes in DISCOVeRY-BMT give confidence that the
325 observed ASSET association is the potential susceptibility locus in the region. The
326 functional significance of variants in this gene in hematopoiesis and its previous
327 recognition as a locus associated with the risk for development of other hematological
328 malignancies, further strengthen the evidence of an association of IRF4 with development
329 of AML and MDS.
330 In addition to *IRF4*, we identified an association between the risk for development of *de*
331 *novo* AML or MDS and higher expression of *AKT1*. *AKT1* is an oncogene which plays a
332 critical role in the *PI3K/AKT* pathway. AML patients frequently show increased *AKT1*
333 activity, providing leukemic cells with growth and survival promoting signals[62] and
334 enhanced *AKT* activation has been implicated in the transformation from MDS to AML
335 and overexpression of *AKT* has been shown to induce leukemia in mice.[63]
336 We also identified AML and MDS gene expression associations with *RASGRP2*, which is
337 expressed in various blood cell lineages and platelets, acts on the *Ras*-related protein
338 Rap and functions in platelet adhesion. GWAS have identified significant variants in this
339 gene associated with immature dendritic cells (% CD32+) and immature fraction of
340 reticulocytes, a blood cell measurement shown to be elevated in patients with MDS

341 versus controls.[39] *RASGRP2* expression has not been studied in relation to AML or MDS,
342 however recently *RASGRP2/Rap1* signaling was shown to be functionally linked to the
343 CD38-associated increased CLL cell migration. The migration of CLL cells into lymphoid
344 tissues because of proliferation induced by B-cell receptor activation is thought to be an
345 important component of CLL pathogenesis.[64] This finding has implications for the design
346 of novel treatments for CD38+ hematological diseases.[64] These data imply the replication
347 of these gene expression associations with the development of AML and MDS are
348 warranted.
349 This is the largest genome-wide AML and MDS susceptibility study to date. Despite our
350 relatively large sample size, the complexity of cytogenetic risk groups in these diseases
351 limits our analysis, particularly with respect to therapy-related AML and MDS.
352 The DISCOVeRY-BMT study population is composed of mostly European American non-
353 Hispanics and thus validation of these associations in a non-white cohort of patients is
354 imperative. Lastly, the use of TWAS is a powerful way to start to prioritize causal genes
355 for follow-up after GWAS, however there are limitations. TWAS tests for association with
356 genetically predicted gene expression and not total gene expression, which includes
357 environmental, technical and genetic components.[65]
358 Our results provide evidence for the impact of common variants on the risk for AML or
359 MDS susceptibility and further characterization of the 6p25.3 locus might provide a more
360 mechanistic basis for the pleiotropic role of *IRF4* in AML and MDS susceptibility. The co-
361 identification of variants in *IRF4* associated with the risk for both myeloid and lymphoid
362 malignancy supports the importance of broader studies that span the spectrum
363 hematologic malignancies.

ACKNOWLEDGEMENTS / CONTRIBUTIONS / FUNDING

This work was supported by grants from the National Institute of Health. LESC and TH were supported by 1R01HL102278 and 1R03CA188733 to perform this work. EK is supported by the Pelotonia Foundation Graduate Student Fellowship. Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the Pelotonia Fellowship Program or The Ohio State University.

ACG was supported by CA9204, Mayo Clinic R25 Training Grant when she performed a majority of this work. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Be the Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; *Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; The Leukemia & Lymphoma

Society; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Merck & Co, Inc.; Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.

*Corporate Members

Authorship Contributions

J.W, A.C-G, L.S-C, and T.E.H designed the research, performed research and analysis, and wrote the manuscript.

C.A.H, D.V, X.S and L.P performed the genotyping.

X.Z., L.P, A.W and G.B performed quality control of genomic data.

All authors reviewed and approved the manuscript.

REFERENCES

1. Walker CJ, Oakes CC, Genutis LK, et al. Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. *Leukemia*. 2019;33(3):771-775.
2. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. *Blood*. 2009;113(22):5575-5582.
3. Lv H, Zhang M, Shang Z, et al. Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia. *Oncotarget*. 2017;8(5):7891-7899.
4. Bhattacharjee S, Rajaraman P, Jacobs KB, et al. A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. *Am J Hum Genet*. 2012;90(5):821-835.
5. Law PJ, Sud A, Mitchell JS, et al. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. *Sci Rep*. 2017;7:41071.
6. Went M, Sud A, Speedy H, et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. *Blood Cancer J*. 2018;9(1):1.
7. Churpek JE. Familial myelodysplastic syndrome/acute myeloid leukemia. *Best Pract Res Clin Haematol*. 2017;30(4):287-289.
8. Gao J, Gentzler RD, Timms AE, et al. Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. *J Hematol Oncol*. 2014;7:36.
9. Goldin LR, Kristinsson SY, Liang XS, Derolf AR, Landgren O, Bjorkholm M. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. *J Clin Oncol*. 2012;30(2):179-183.
10. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet*. 2016;48(3):245-252.
11. Gamazon ER, Wheeler HE, Shah KP, et al. A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet*. 2015;47(9):1091-1098.
12. Hahn T, Sucheston-Campbell LE, Preus L, et al. Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2015;21(9):1679-1686.
13. Clay-Gilmour AI, Hahn T, Preus LM, et al. Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. *Blood Adv*. 2017;1(20):1717-1728.
14. Karaesmen E, Rizvi AA, Preus LM, et al. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. *Blood*. 2017;130(13):1585-1596.
15. Zhu Q, Yan L, Liu Q, et al. Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. *Blood*. 2018;131(22):2490-2499.
16. Yan L, Ma C, Wang D, et al. OSAT: a tool for sample-to-batch allocations in genomics experiments. *BMC Genomics*. 2012;13:689.
17. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006;38(8):904-909.
18. Das S, Forer L, Schonherr S, et al. Next-generation genotype imputation service and methods. *Nat Genet*. 2016;48(10):1284-1287.
19. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48(10):1279-1283.
20. Lee CH, Eskin E, Han B. Increasing the power of meta-analysis of genome-wide association studies to detect heterogeneous effects. *Bioinformatics*. 2017;33(14):i379-i388.

21. Deary IJ, Yang J, Davies G, et al. Genetic contributions to stability and change in intelligence from childhood to old age. *Nature*. 2012;482(7384):212-215.
22. Lee SH, Yang J, Goddard ME, Visscher PM, Wray NR. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. *Bioinformatics*. 2012;28(19):2540-2542.
23. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet*. 2011;88(1):76-82.
24. Mitchell JS, Johnson DC, Litchfield K, et al. Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. *Sci Rep*. 2015;5:12473.
25. Lu Y, Ek WE, Whiteman D, et al. Most common 'sporadic' cancers have a significant germline genetic component. *Hum Mol Genet*. 2014;23(22):6112-6118.
26. Lee SH, Harold D, Nyholt DR, et al. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. *Hum Mol Genet*. 2013;22(4):832-841.
27. Battle A, Mostafavi S, Zhu X, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. *Genome Res*. 2014;24(1):14-24.
28. Võsa U, Claringbould A, Westra H-J, et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. *bioRxiv*. 2018:447367.
29. Carithers LJ, Ardlie K, Barcus M, et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. *Biopreserv Biobank*. 2015;13(5):311-319.
30. Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics*. 2016;32(20):3207-3209.
31. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. *Nature*. 2015;518(7539):317-330.
32. Cairns J, Freire-Pritchett P, Wingett SW, et al. CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. *Genome Biol*. 2016;17(1):127.
33. Mifsud B, Tavares-Cadete F, Young AN, et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nat Genet*. 2015;47(6):598-606.
34. Spurrell CH, Dickel DE, Visel A. The Ties That Bind: Mapping the Dynamic Enhancer-Promoter Interactome. *Cell*. 2016;167(5):1163-1166.
35. Schofield EC, Carver T, Achuthan P, et al. CHiCP: a web-based tool for the integrative and interactive visualization of promoter capture Hi-C datasets. *Bioinformatics*. 2016;32(16):2511-2513.
36. Schoenfelder S, Javierre BM, Furlan-Magaril M, Wingett SW, Fraser P. Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions. *J Vis Exp*. 2018(136).
37. Yu Y, Ouyang Y, Yao W. shinyCircos: an R/Shiny application for interactive creation of Circos plot. *Bioinformatics*. 2018;34(7):1229-1231.
38. Walker CJ, Oakes CC, Genutis LK, et al. Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. *Leukemia*. 2018.
39. Astle WJ, Elding H, Jiang T, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell*. 2016;167(5):1415-1429 e1419.
40. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. *Nat Genet*. 2008;40(10):1204-1210.
41. Havelange V, Pekarsky Y, Nakamura T, et al. IRF4 mutations in chronic lymphocytic leukemia. *Blood*. 2011;118(10):2827-2829.
42. Pratt G, Fenton JA, Allsup D, et al. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. *Br J Haematol*. 2010;150(3):371-373.

43. Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. *Blood*. 2011;118(1):139-147.
44. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. *Nature*. 2008;454(7201):226-231.
45. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res*. 2012;22(9):1790-1797.
46. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. 2019.
47. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. *Nat Rev Cancer*. 2017;17(9):513-527.
48. Sampson JN, Wheeler WA, Yeager M, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst*. 2015;107(12):djv279.
49. Visser M, Palstra RJ, Kayser M. Allele-specific transcriptional regulation of IRF4 in melanocytes is mediated by chromatin looping of the intronic rs12203592 enhancer to the IRF4 promoter. *Hum Mol Genet*. 2015;24(9):2649-2661.
50. Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. *Nucleic Acids Res*. 2014;42(5):2976-2987.
51. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012;40(Database issue):D930-934.
52. Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun*. 2016;7:12050.
53. Vijayakrishnan J, Qian M, Studd JB, et al. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. *Nat Commun*. 2019;10(1):5348.
54. Went M, Sud A, Speedy H, et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. *Blood Cancer J*. 2018;9(1):1.
55. Slager SL, Camp NJ, Conde L, et al. Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. *Br J Haematol*. 2012;159(5):572-576.
56. Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. *Blood*. 2008;112(9):3798-3806.
57. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal center B-cell differentiation. *Immunol Rev*. 2012;247(1):73-92.
58. Bisig B, Gaulard P, de Leval L. New biomarkers in T-cell lymphomas. *Best Pract Res Clin Haematol*. 2012;25(1):13-28.
59. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. *Br J Haematol*. 2002;117(2):366-372.
60. Adamaki M, Lambrou GI, Athanasiadou A, Tzanoudaki M, Vlahopoulos S, Moschovi M. Implication of IRF4 aberrant gene expression in the acute leukemias of childhood. *PLoS One*. 2013;8(8):e72326.
61. Allan JM, Sunter NJ, Bailey JR, et al. Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. *Leukemia*. 2010;24(4):877-881.
62. Tang Y, Halvarsson C, Nordigarden A, et al. Coexpression of hyperactivated AKT1 with additional genes activated in leukemia drives hematopoietic progenitor cells to cell cycle block and apoptosis. *Exp Hematol*. 2015;43(7):554-564.

63. Kharas MG, Okabe R, Ganis JJ, et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. *Blood*. 2010;115(7):1406-1415.
64. Mele S, Devereux S, Pepper AG, Infante E, Ridley AJ. Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells. *Blood Adv*. 2018;2(13):1551-1561.
65. Wainberg M, Sinnott-Armstrong N, Mancuso N, et al. Opportunities and challenges for transcriptome-wide association studies. *Nature Genetics*. 2019;51(4):592-599.

Figure Legends

Figure 1. ASSET analysis and associations by AML and MDS subgroup
Forest plot of the odds ratios (OR) for the association between rs12203592 in *IRF4* and MDS and AML subtypes. The variant resides in the Chromosome 6 outside the major histocompatibility complex region. Studies were weighted by inverse of the variance of the log (OR). The solid grey vertical line is positioned at the null value (OR=1); values to the right represent risk increasing odds ratios. Horizontal lines show the 95% CI and the box is the OR point estimate for each case-control subset with its area proportional to the weight of the patient group. The diamond is the overall effect estimated by ASSET, with the 95% CI given by its width.

Figure 2. *IRF4* region with AML and MDS associated SNP p-values annotated with previous GWAS and Roadmap Epigenome Chromatin States.
A. ASSET analysis AML and MDS SNP associations in the *IRF4* region. The x-axis is the chromosome position in kilobase pairs and y-axis shows the –log10 (p-values) for de novo AML and MDS susceptibility. The associated SNPs in the *IRF4* region, rs12203592 and rs62389423, are highlighted with sky blue lines drawn through the point to show the relationship of the variant to GWAS hits and Roadmap Epigenome data (2C). rs12203592 and rs62389423 show moderate linkage disequilibrium (r^2=0.7); rs62389423 and rs62389424 are almost perfectly correlated (r^2=.95).
B. Previously reported GWAS SNPs in the *IRF4* region. Phenotypes are color coded and all variants are associated at $P< 5 \times 10^{-8}$.
C. Genes in the region annotated with the chromatin-state segmentation track (ChromHMM) from Roadmap Epigenome data for all blood, T-cell, HSC and B-cells. The cell line numbers shown down the left side correspond to specific epigenome road map cell lines. E029:Primary monocytes from peripheral blood; E030:Primary neutrophils from peripheral blood; E031:Primary B cells from cord blood; E032:Primary B Cells from peripheral blood; E033:Primary T Cells from cord blood; E034:Primary T Cells from blood; E035:Primary hematopoietic stem cells; E036:Primary hematopoietic stem cells short term culture; E037:Primary T helper memory cells from peripheral blood 2; E038:Primary T help naïve cells from peripheral blood; E039:Primary T helper naïve cells from peripheral blood; E040:Primary T helper memory cells from peripheral blood 1; E041:Primary T helper cells PMA-Ionomycin stimulated; E042:Primary T helper 17 cells PMA-Ionomycin stimulated; E043:Primary T helper cells from peripheral blood; E044:Primary T regulatory cells from peripheral blood; E045:Primary T cells effector/memory enriched from peripheral blood; E046:Primary Natural Killer cells from peripheral blood; E047:Primary T CD8 naïve cells from peripheral blood; E048:Primary T CD8 memory cells from peripheral blood; E-50:Primary hematopoietic stem cells G-CSF mobilized Female; E-51:Primary hematopoietic stem cells G-CSF mobilized Male; E062:Primary Mononuclear Cells from Peripheral Blood; E0116 Lymphoblastic Cell Line. The colors indicate chromatin states imputed by ChromHMM and shown in the key titled “Roadmap Chromatin State”

Figure 3. Manhattan plot of the *de novo* AML and MDS GWAS and TWAS.
The plot represents the TWAS P-values (top) of each gene and *de novo* AML and MDS GWAS P-values (bottom) of each SNP included in the case-control association study. Significant and suggestive genes are highlighted in orange and labelled by their gene symbols. The orange horizontal line on the top represents the transcriptome-wide significance threshold of $P=4.5\times10^{-6}$. The orange horizontal line on the bottom represents the genome-wide threshold of $P=5.0\times10^{-8}$.

Figure 4. Regional plots of PrediXcan-TWAS and SNP associations with AML and MDS
Each box represents PrediXcan-TWAS significant genes *AKT1*, *IRF4* and *RASGRP2* +/- 0.5 megabases. The grey shaded bars represent the gene, where height is gene expression association and width is gene region in base pairs and the purple dots represent SNP associations with AML and MDS -log10 (P-values) are shown on the y-axis. Green and red lines denote the transcriptome-wide and genome wide significant P-values, respectively.

Table 1. DISCOVeRY-BMT Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Patient and Control Characteristics

Patient and Donor Characteristics	Cases Cohort 1 / Cohort 2 N= 1627 (%) / 682 (%)	Controls Cohort 1 / Cohort 2 N= 2052 (%) / 762 (%)
Age, years		
Median (range)	50 (<1-74.5) / 52 (<1-78)	33 (18-61) / 31 (18-60)
Sex		
Females	741 (46) / 312 (46)	656 (32) / 209 (27)
Disease		
AML, all cases	**1282 (79) / 487 (71)**	**-**
de novo AML	**1164 (72) / 454 (66)**	**-**
de novo AML with normal cytogenetics	**373 (23) / 170 (25)**	**-**
de novo AML with abnormal cytogenetics	**595 (37) / 241 (35)**	**-**
By Cytogenetic Subtype:		
Core Binding Factor	67 (11) / 32 (13)	-
MLL	72 (12) / 48 (20)	-
Ph+ t(9;22)	5 (1) / 1 (0)	-
APL t(15;17)	18 (3) / 3 (1)	-
Any translocation	97 (15) /35 (15)	-
Trisomy 8	103 (17) / 22 (9)	-
Trisomy 13, 21 or 22	52 (9) / 24 (9)	-
del5/del7	123 (21) / 55 (23)	-
Any Trisomy	195 (33) / 92 (38)	-
Any Monosomy	153 (26) / 50 (21)	-
>3 cytogenetic abnormalities	213 (36) / 88 (37)	-
therapy-related AML	**113 (7) / 33 (5)**	**-**
By Prior Diagnosis[2]:		
Breast Cancer	39 (35) / 12 (36)	-
Non-Hodgkin Lymphoma	20 (18) / 3 (9)	-
Hodgkin Lymphoma	11 (10) / 3 (9)	-
Sarcoma	9 (3) / 8 (9)	-
Gynecologic Cancer	6 (5) / 2 (6)	-
Acute Lymphoblastic Leukemia	4 (4) / 2 (6)	-
Testicular Cancer	4 (4) / 2 (6)	-
Other Disease	20 (18) / 4 (12)	

MDS, all cases	**345 (21) / 195 (29)**	
de novo MDS	**294 (18) / 150 (22)**	
By WHO subtype[2]:		
MDS-unclassified[3]	58 (17) / 35 (18)	
RA, RA-RS	91 (26) / 28(15)	
RAEB-1, RAEB-2	153 (44) / 89 (46)	
Chronic Myelomonocytic Leukemia	42 (12) / 16 (8)	
RCMD, RCMD-RS	0 (0) / 25 (13)	
therapy-related MDS	**51 (3) / 45 (7)**	
By Prior Diagnosis[2]:		
Non-Hodgkin Lymphoma	15 (29) / 12 (27)	-
Breast Cancer	8 (16) / 7 (16)	-
Hodgkin Lymphoma	6 (12) / 2 (4)	-
Acute Lymphoblastic Leukemia	4 (8) / 4 (9)	-
Acute Myeloid Leukemia	4 (8) / 4 (9)	-
Chronic Lymphocytic Leukemia	2 (4) / 3 (6)	-
Sarcoma	1 (2) / 5 (11)	-
Other diseases	10 (20) / 9 (20)	-

[1]percentage of patient subgroup reflects the percentage of the total number of AML and MDS cases in each cohort; [2]percentage of patient subgroup reflects the percentage of the cases of corresponding disease subgroups in each cohort; [3]one individual had 5q-syndrome;
RAEB=Refractory Anemia Excess Blasts; RCMD=Refractory Cytopenia with Multilineage Dysplasia; RCMD-RS=Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts; RARS=Refractory Anemia with Ring Sideroblasts.

Figure 1. ASSET analysis and associations by AML and MDS subgroup

rs12203592

Phenotype	OR	95% CI	Adjusted P	N
Null				
therapy-related AML	*1.18*	*(0.86,1.63)*	*1.0*	*146*
Positive				
de novo abnormal cyto AML	*1.32*	*(1.15,1.53)*	*4.8e-04*	*836*
de novo normal cyto AML	*1.32*	*(1.11,1.56)*	*5.3e-03*	*543*
de novo MDS	*1.39*	*(1.15,1.66)*	*5.0e-04*	*444*
therapy-related MDS	*2.07*	*(1.47,2.90)*	*2.6e-05*	*96*
ASSET	**1.38**	**(1.26,1.51)**	**2.8e-12**	**1919**



Figure 2. *IRF4* region with AML and MDS associated SNP p-values annotated with previous GWAS and Roadmap Epigenome Chromatin States.



Figure 3. Manhattan plot of the *de novo* AML and MDS GWAS and TWAS.



Figure 4. Regional plots of PrediXcan-TWAS and SNP associations with AML and MDS



Supplemental Figure 1. Genome wide associations by cytogenetic subtype in DISCOVeRY-BMT

Shown are the genome-wide *P* values by subtype from the meta-analysis of DISCOVeRY-BMT cohorts, including a total of 2158 AML and MDS cases and 2814 controls. The dashed horizontal line represents the suggestive threshold of $P=5.0\times10^{-6}$. The orange horizontal line represents the genome-wide significance threshold of $P=5.0\times10^{-8}$.





Supplemental Figure 2. Significant chromatin interactions between the promoter region containing AML and MDS susceptibility variant, rs12203592 and the target region containing the previously identified CLL and HL susceptibility variant, rs9392017

The circular plots show significant chromatin interactions between bait-target pairs, defined as a CHICAGO score >=5, designated with red arcs, generated by promoter capture HI-C experiments in multiple cell lines. Moving from the outside of the circles inward we see base pair position on chromosome 6 in Kb, protein coding genes are shown in grey (*HUS1B, EXOC2, DUSP22* and *IRF4)*, the ENCODE roadmap epigenome chromatin states for **(LEFT)** E116: lymphoblastoid cell line and the following cell lines **(RIGHT)** E035:Primary hematopoietic stem cells; E036:Primary hematopoietic stem cells short term culture; E-50:Primary hematopoietic stem cells G-CSF mobilized Female; E-51:Primary hematopoietic stem cells G-CSF mobilized Male.

This figure shows chromatin looping from the reference of the CLL and HL susceptibility region containing rs9392017 which illustrates this target region interacts with only few adjacent areas and only one transcriptional start site which contains rs12203592 providing support for the role of *IRF4* in CLL, HL, AML and MDS.